山德士诺华公司的甲氨蝶呤片疗效怎么样？

Psoriasis is an inflammatory skin disease induced by environmental, genetic, immune and other factors. The pathogenesis is still unclear. Sandoz and Novartis' tablets are used to treat people with psoriasis.

Sandoz, a member of the Novartis Group, is the world's second largest generic pharmaceuticals company. Sandoz is a global leader in generic pharmaceuticals, developing, manufacturing and marketing pharmaceuticals not subject to patent protection, as well as pharmaceutical active substances and bioactive substances. How effective are methotrexate tablets from Sandoz and Novartis?

The clinical trial included 30 patients with moderate to severe plaque psoriasis and divided them into Yisaipu group (15 cases) and Yisaipu + methotrexate group (15 cases). The treatment course was 24 weeks. Enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR were used to detect the concentrations and mRNA expression levels of IL-17A and TNF-α in serum and peripheral blood mononuclear cells of the two groups of patients before and after treatment.

The results showed that before treatment, serum IL-17A and TNF-α levels as well as IL-17A and TNF-α in peripheral blood PBMCs of patients in the Yisaipu + group and Yisaipu group The expression of mRNA was significantly higher than that of the healthy control group; after treatment, the serum IL-17A and TNF-α concentrations in the Yisaipu + methotrexate group (142.67±14.82, 70.07±25.02) and the IL-17A and TNF-α in peripheral blood PBMC The mRNA expressions (1.12±0.33, 2.50±1.04) were significantly lower than those in the Yisaipu group (serum IL-17A and TNF-α concentrations were 163.54±23.18 and 91.98±14.62 respectively; IL-17A and TNF-α mRNA expressions in peripheral blood PBMC were 1.56±0.77 and 3.61±2.14 respectively).

Recommended related hot articles: /newsDetail/92580.html